Navigation Links
GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
Date:2/25/2008

ATLANTA, Feb. 25 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), http://www.geovax.com, an Atlanta based biotechnology company, announced their HIV/AIDS vaccine is one of the select few to move forward into Phase 2a human trials by the HIV Vaccine Trials Network (HVTN), a network supported by the National Institutes of Health (NIH).

GeoVax's AIDS vaccine is believed to be only the fifth [5th] HIV/AIDS vaccine to be selected to move forward into Phase 2a human trials conducted by the HVTN. In contrast, it was approximately HVTN's 65th vaccine evaluated in Phase 1 human trials.

Most recently, GeoVax Senior Vice President of Research & Development, Dr. Harriet Robinson, and President, Don Hildebrand, attended a meeting with key HTVN officials in Seattle, Washington to plan and prepare necessary documents for the next phase of testing of GeoVax's promising HIV/AIDS vaccine, namely Phase 2a human trials designated as Protocol # HVTN 205.

Attended by over 20 HVTN personnel and key GeoVax personnel, this event included individuals instrumental in organizing and implementing human clinical trials designed to evaluate the GeoVax HIV/AIDS vaccine. The newly planned Phase 2 trials are tentatively scheduled to start mid-2008 and will involve up to 500 participants at several locations in the USA.

"We are delighted that our HIV/AIDS vaccine has been selected to move forward into Phase 2 trials. Our vaccine continues to demonstrate the promise of not only being safe but also effective at eliciting potentially protective immune responses," stated Dr Harriet Robinson, Senior Vice President, Research & Development at GeoVax.

"GeoVax is extremely pleased to have passed the significant hurdles required to move into Phase 2 trials. Only a handful of AIDS vaccines have reached the Phase 2 level of clinical evaluation with the HVTN, including the previously failed vaccines
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
2. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
3. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
4. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
5. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
6. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
7. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
8. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
11. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ay Someday Inform Treatments for Spinal Cord, Othe...ire-USNewswire/ -- A protein that enables,nerve ce...e in controlling,the developing nervous system. Re...ions to form among nerve cells may provide a basis...njuries to their nervous system,including spinal ...
(Date:10/8/2008)... program to evaluate TAXUS(R) Element(TM) Platinum...NATICK, Mass., Oct. 8 /- Bo...nounced that it has completed enrollment in,the PE...ird-generation,TAXUS(R) Element(TM) paclitaxel-elu...has enrolled nearly 1,500 patients at 100 U.S. and...
(Date:10/7/2008)...ct. 7 /- Prometheus Laboratories Inc....ced findings from its,development of PROMETHEUS(R)... irritable bowel syndrome (IBS). The findings sugg...rticular biomarkers in blood samples,between IBS a...iomarkers,combined with a proprietary algorithm, ...
(Date:10/7/2008)...LEXX Trial Presented at the Osteoarthritis Researc...RSIPPANY, N.J., Oct. 7 /- Ferring Pha...the FLEXX Trial of Osteoarthritis of the,Knee, sho...ighly pure,non-avian high molecular weight form of...ior to intra-articular saline (IA-saline) for the ...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Specific antagonism lowers blood pressure 63 1New prion protein discovered by Canadian scientists may offer insight into mad cow disease 58 1New prion protein discovered by Canadian scientists may offer insight into mad cow disease 58 2Preclinical study suggests organ transplant drug may aid in lupus fight 53 1Preclinical study suggests organ transplant drug may aid in lupus fight 53 2First biomarker discovered that predicts prostate cancer outcome 48 1First biomarker discovered that predicts prostate cancer outcome 48 2First biomarker discovered that predicts prostate cancer outcome 48 3First biomarker discovered that predicts prostate cancer outcome 48 4
... from the ASSERT Trial Presented at EULAR, BARCELO... Data,presented today at the European League Again...Rheumatology showed that patients with,ankylosing ...mab),over two years experienced significant improv...eated patients showed sustained,reductions in spin...
...sults Published in Cancer Research, TARRYTOWN, N.Y...,Corporation today announced the results of scient...MPC-6827) is effective in treating,multiple types ...hanism by which MPC-6827 exerts its effects, and (...proteins known to be involved,in cancer drug resis...
Other Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 2New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 3New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 4New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 5New Research Demonstrates Broad Efficacy of Azixa (MPC-6827),Against Multiple Tumor Types and in Drug Resistant Cell Lines 6
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...ster that took place two decades ago, scientists h... not as harmful// as it is thought to be. This n...level of toleration or limit of radioactive exposu...sidered safe. This might stir up a debate over nuc...
...nt of $6 million for the Florida State University ...lexia in children.// The schedule involves unders.... The grant will fund the creation of a National ...linary Learning Disabilities Center at FSU. The ce...
...ve found that any kind of exercise will help to pr...Todd M. Manini, an exercise physiologist at the U....of reports out there saying that self-reported exe...ial. We wanted to see if just usual daily activity...
...ion called aortic dissection (a tear in the larges...//. His death brought the focus on this deadly dis... and genetic disorders. Now, researchers have publ... dissection, showing that 90 percent of patients w...
Other Medicine News:Health News:Research Fund for FSU to Eradicate Dyslexia 2Health News:Physical Activity of any kind to Prolong Life 2Health News:Aortic Dissection - A Deadly Condition 2Health News:Aortic Dissection - A Deadly Condition 3Health News:Aortic Dissection - A Deadly Condition 4
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: